

FASKEN

Fasken Martineau DuMoulin LLP
Barristers and Solicitors
Patent and Trade-mark Agents

333 Bay Street, Suite 2400
P.O. Box 20
Toronto, Ontario M5H 2T6
Canada

T +1 416 366 8381
+1 800 268 8424
F +1 416 364 7813
fasken.com

May 25, 2021

British Columbia Securities Commission
Alberta Securities Commission
Ontario Securities Commission

Dear Sirs/Mesdames:

**Re: BetterLife Pharma Inc. (the “Issuer”)
Prospectus Supplement to the Final Short Form Base Shelf Prospectus dated April
26, 2021**

We refer to the prospectus supplement dated May 25, 2021 to the short form base shelf prospectus dated April 26, 2021 of the Issuer in relation to the offering of units each comprised of one common share and one common share purchase warrant (the “**Prospectus Supplement**”).

We hereby consent to the reference to our firm name in the introduction and under the heading “Legal Matters” in the Prospectus Supplement.

We confirm that we have read the Prospectus Supplement and have no reason to believe that there are any misrepresentations in the information contained in the Prospectus Supplement that is within our knowledge as a result of the services we performed in connection with such the preparation of the Prospectus Supplement.

This letter is delivered to the addressees pursuant to the requirements of Section 4.2(a)(vii) of National Instrument 44-101.

Yours truly,

“FASKEN MARTINEAU DuMOULIN LLP”

